Publications by authors named "M HOLMBERG"
Introduction: Making decisions about the appropriate level of care is a significant challenge for healthcare professionals, especially when older patients present with diffuse symptoms. Collaboration between ambulance services and primary care may promote a comprehensive understanding of patient needs. However, such collaboration remains limited, potentially leading to lower care quality and higher costs.
View Article and Find Full Text PDFBackground: Hyperkalaemia is a life-threatening electrolyte disturbance and also a potential cause of cardiac arrest. The objective was to assess the effects of acute pharmacological interventions for the treatment of hyperkalaemia in patients with and without cardiac arrest.
Methods: The review was reported according to PRISMA guidelines and registered on PROSPERO (CRD42023440553).
Objective: In moderate-to-severe Graves' orbitopathy, rituximab is recommended as second-line therapy in patients nonresponsive to intravenous glucocorticoids. We aimed to evaluate rituximab as early second-line therapy, as data are scarce and contradictory.
Methods: In this nonrandomized, controlled, interventional study, patients with Graves' orbitopathy started on intravenous glucocorticoids.
Article Synopsis
- The study focuses on detecting multijet signatures from proton-proton collisions at a high energy of 13 TeV, analyzing a dataset totaling 128 fb^{-1}.
- A special data scouting method is utilized to pick out events with low combined momentum in jets.
- This research is pioneering in its investigation of electroweak particle production in R-parity violating supersymmetric models, particularly examining hadronically decaying mass-degenerate higgsinos, and it broadens the limits on the existence of R-parity violating top squarks and gluinos.
Background: Longitudinal studies investigating hormone therapy in transgender individuals are rare and often limited to 1- to 2-year follow-up periods.
Objectives And Methods: We examined changes in body composition, muscle volumes, and fat distribution as well as muscle strength, arterial stiffness, and cardiometabolic biomarkers in both transgender men (TM; n = 17, age 25 ± 5 years) and transgender women (TW; n = 16, age 28 ± 5 years) at baseline and after 1 and 5-6 years of hormone therapy in a longitudinal prospective cohort design. Whole-body and regional fat and muscle volumes were analyzed using magnetic resonance imaging, and blood samples were taken.